IP Library › Granted Patent US 8,155,744
Granted Patent B2
US 8,155,744 · App. 12/333,162 · Granted Apr 10, 2012

Neuromodulatory methods for treating pulmonary disorders

Assignee: The Cleveland Clinic Foundation
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,155,744
App. No.
12/333,162
Granted
Apr 10, 2012
Kind
B2
Abstract

A method for treating a pulmonary disorder in a subject includes inserting a therapy delivery device into a vessel of the subject, advancing the therapy delivery device to a point adjacent an intraluminal target site of the autonomic nervous system, and activating the therapy delivery device to delivery a therapy signal to the intraluminal target site to treat the pulmonary disorder. The intraluminal target site is in electrical communication with nervous tissue selected from the group consisting of a spinal nerve, a postganglionic fiber of a spinal nerve, a sympathetic chain ganglion, a thoracic sympathetic chain ganglion, a cervical ganglion, a lower cervical ganglion, an inferior cervical ganglion, an intramural ganglion, a splanchnic nerve, an esophageal plexus, a cardiac plexus, a pulmonary plexus, an anterior pulmonary plexus, a posterior pulmonary plexus, a celiac plexus, a hypogastric plexus, an inferior mesenteric ganglion, a celiac ganglion, and a superior mesenteric ganglion.

Claims (34)

1. A method for treating asthma in a subject, said method comprising the steps of:

inserting a therapy delivery device into a pulmonary artery of the subject;

advancing the therapy delivery device to a point substantially adjacent an intraluminal target site of the autonomic nervous system (ANS); and

activating the therapy delivery device to deliver a therapy signal to the intraluminal target site of the ANS to treat the asthma;

wherein the intraluminal target site is in electrical communication with nervous tissue selected from the group consisting of a spinal nerve, pre- or post-ganglionic autonomic fibers, a sympathetic chain ganglion, a thoracic sympathetic chain ganglion, a cervical ganglion, a lower cervical ganglion, an inferior cervical ganglion, an intramural ganglion, a splanchnic nerve, an esophageal plexus, a cardiac plexus, a pulmonary plexus, an anterior pulmonary plexus, a posterior pulmonary plexus, a celiac plexus, a hypogastric plexus, an inferior mesenteric ganglion, a celiac ganglion, and a superior mesenteric ganglion.

2. The method of claim 1 , wherein the therapy delivery device is inserted into a left pulmonary artery.

3. The method of claim 2 , wherein the therapy delivery device is advanced to a point in the left pulmonary artery that is crossed by the anterior pulmonary plexus.

4. The method of claim 2 , wherein the therapy delivery device is advanced to a portion of the left pulmonary artery so that the therapy delivery device is in electrical communication with the anterior pulmonary plexus.

5. The method of claim 1 , wherein the therapy delivery device is advanced to a point substantially adjacent the anterior pulmonary plexus.

6. The method of claim 1 further comprising the steps of:

sensing a bodily activity associated with the asthma;

generating a sensor signal based on the bodily activity; and

activating the therapy delivery device to adjust application of the therapy signal to the intraluminal target site in response to the sensor signal to treat the asthma.

7. The method of claim 1 , said step of activating the therapy delivery device further including increasing the sympathetic activity of the nervous tissue.

8. A method for treating asthma in a subject, said method comprising the steps of:

inserting a therapy delivery device into a pulmonary artery of the subject;

advancing the therapy delivery device to a point substantially adjacent an intraluminal target site of the ANS; and

activating the therapy delivery device to deliver a therapy signal to the intraluminal target site of the ANS to treat the asthma.

9. The method of claim 8 , wherein the intraluminal target site is in electrical communication with nervous tissue selected from the group consisting of a pulmonary plexus, an anterior pulmonary plexus, and a posterior pulmonary plexus.

10. The method of claim 8 , wherein the therapy delivery device is inserted into a left pulmonary artery.

11. The method of claim 10 , wherein the therapy delivery device is advanced to a point in the left pulmonary artery that is crossed by the anterior pulmonary plexus.

12. The method of claim 8 further comprising the steps of:

sensing a bodily activity associated with the asthma;

generating a sensor signal based on the bodily activity; and

activating the therapy delivery device to adjust application of the therapy signal to the intraluminal target site in response to the sensor signal to treat the asthma.

13. The method of claim 8 , said step of activating the therapy delivery device further including increasing the sympathetic activity of the nervous tissue.

14. A method for treating asthma in a subject, said method comprising the steps of:

inserting a therapy delivery device into an esophagus of the subject;

advancing the therapy delivery device to a point substantially adjacent an anterior pulmonary plexus; and

activating the therapy delivery device to deliver a therapy signal to the anterior pulmonary plexus to treat the asthma.

15. The method of claim 14 further comprising the steps of:

sensing a bodily activity associated with the asthma;

generating a sensor signal based on the bodily activity; and

activating the therapy delivery device to adjust application of the therapy signal to the anterior pulmonary plexus in response to the sensor signal to treat the asthma.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Feb 26, 2009
From: REZAI, ALI R.
To: THE CLEVELAND CLINIC FOUNDATION
Reel/Frame 022313/0930 →
Continuity (2)
Provisional Application 61013378 · Dec 13, 2007
Related Publication 20090155336A1 · Jun 18, 2009